New England Journal of Medicine , “One Pivotal Trial, the New Default Option for FDA Approval – Ending the Two-Trial Dogma,” by Vinay Prasad, M.D., M.P.H.1 and Martin A. Makary, M.D., M.P.H.1

Read Publication